What are the future trends of medical devices? In the rapidly evolving landscape of healthcare, staying informed about the latest advancements in medical technology is essential for professionals and ...
Independence Blue Cross has begun excluding coverage for 18 months for therapies — but not cancer drugs — that have an ...
Capricor's biologics license application for deramiocel (CAP-1002) is draws largely on the Phase 2 HOPE-2 trial and its ...
Capricor Therapeutics seeks US FDA approval for deramiocel for the treatment of Duchenne muscular dystrophy: San Diego Saturday, January 4, 2025, 15:00 Hrs [IST] Capricor Therapeu ...
Deramiocel is a cell therapy that has healing effects in muscle cells. If approved, deramiocel would be a once-quarterly ...
Capricor stock gains 8% upon completing the rolling submission of the BLA for its lead asset, deramiocel, to treat DMD cardiomyopathy in the United States.
Capricor Therapeutics has completed its US marketing application for deramiocel, a cell therapy the US biotech hopes will ...
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology firm specializing in innovative cell and exosome-based therapies for rare diseases, finalized the submission of its Biologics License ...
This milestone has triggered a $10 million milestone payment to Capricor from Nippon Shinyaku, the company's distribution ...
Shares of Capricor Therapeutics ($CAPR) were up 8.41% up on Thursday after the rare diseases-focused biotech said it ...
US biotech Capricor Therapeutics today announced the completion of the submission of its Biologics License Application (BLA) ...
"The submission of the BLA marks a pivotal step for Capricor and those impacted by DMD. This BLA is the culmination of a body of work that has been focused on bringing this potentially ...